Transitioned from a clinical development firm to a commercially focused enterprise following the June 2025 NDA submission for cytisinicline.

Attributed strong clinical momentum to the ORCA-OL study, which demonstrated safety and tolerability over 52 weeks, addressing long-term treatment concerns.

Identified a significant market opportunity in the 6 million COPD smokers in the U.S., where post-hoc data showed cytisinicline significantly improved quit rates.

Pivoted to a lean, omnichannel commercial model to address the reality that 75% of primary care physicians no longer meet with traditional medical representatives.

Integrated AI and machine learning into the 'asset factory' to automate customer engagement and generate predictive insights for precision marketing.

Strategic selection of Adare Pharma Solutions for U.S. manufacturing aims to secure the supply chain and mitigate risks from international tariffs and importation uncertainties.

Anticipates a commercial launch in the first half of 2027, allowing time for manufacturing scale-up and the establishment of a robust U.S. supply chain.

Leveraging the Commissioner's National Priority Voucher to expedite the vaping cessation indication, targeting a review timeline of 1 to 2 months.

Planning the ORCA-V2 Phase III trial for vaping cessation with site selection and principal investigator identification currently underway.

Focusing 2026 efforts on the 'Will Power' awareness campaign to reframe nicotine dependence as a medical condition rather than a personal failure.

Assumes a slow initial 6-month launch ramp due to standard 'new-to-market' payer blocks despite favorable Affordable Care Act coverage requirements.

Disclosed two FDA GMP inspection observations at the current NDA-named manufacturer, prompting an accelerated technology transfer to Adare Pharma Solutions.

Maintains a strategic stockpile of raw starting material sufficient for more than 3 years of market demand to ensure long-term supply continuity.

Noted that while the PDUFA date remains June 20, 2026, the transition to U.S.-based manufacturing with Adare is intended to ensure supply reliability for the commercial launch expected in the first half of 2027.

Highlighted the geopolitical rationale for onshoring manufacturing to the U.S. to provide redundancy and contingency capacity.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management explained the gap is primarily driven by the need to get drug product into the supply chain and finalize trade distribution logistics.

The additional time allows for further engagement with advocacy groups and policymakers to optimize the launch environment.

Management clarified that Adare will be added to the NDA post-approval, likely in Q3, as a contingency and long-term U.S. supplier.

The current manufacturer is addressing FDA observations through a remedial action plan, but Achieve is prioritizing U.S. onshoring for security.

Reported over 40 touchpoints with payers in Q1, noting high interest due to the differentiated clinical profile and unmet need.

Management declined to provide specific pricing but noted the ICER report affirmed the need for immediate payer access.

Management dismissed concerns over the three-times-daily (TID) dosing, citing a 75% adherence rate in the 52-week ORCA-OL trial.

Patients reported that TID dosing aligned well with mealtime cravings, providing a psychological benefit during the quitting process.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.